Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2152W HIGH $3.58
Volume
1.57 M
Value Traded
35.73 K
Short % Float
2.88%
+8.85%Week
-49.59%1 Month
+367.68%3 Month
+104.29%6 Month
-99.84%5 Year
-99.91%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
869.10 K
EPS (TTM)
-10.26
P/E Ratio
-
Ent. Value
-9.93 M
Total Shares
706.59 K
Float Shares
690.00 K
Insiders
2.25%
Institutions
2.69%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SCNI Catalyst Timeline
Dated clinical, regulatory and corporate events for Scinai Immunotherapeutics Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Scinai Immunotherapeutics Ltd.
432Total events
6Upcoming
65Tier-1 (high impact)
2015 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Other Regulator MilestoneEx-US Regulatory
Scinai regained compliance with Nasdaq Listing Rule 5550(a)(2)
◆Manufacturing MilestoneCMC / Inspection
Validation of robotic aseptic fill & finish system targeted for completion
◆FDA Feedback ReceivedIL-17FDA Meeting
Advanced to final interview stage of FENG review process for local intradermal IL-17 NanoAb program
◆Other Regulator MilestonePC111Ex-US Regulatory
Funding decision expected for FENG grant application
pemphigus vulgaris, Stevens-Johnson Syndrome/Toxic Epidermal Necrolysissource ↗
●Oral PresentationPresentation
Leadership team to lead strategic roundtable discussion at 7th Dermatology Drug Development Summit Europe
●Quarterly UpdateCorporate
Completion of strategic corporate reorganization establishing dedicated CDMO platform and lean R&D structure
◆FDA Feedback ReceivedPC111FDA Meeting
Submitted revised FENG grant application for PC111
pemphigus, Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN)source ↗
◆FDA Feedback ReceivedIL-17FDA Meeting
Advanced through initial evaluation stage of Polish FENG grant application for systemic IL-17 bispecific NanoAb
▼Quarterly UpdateCorporate
Received Nasdaq notification regarding minimum bid price non-compliance
▼Other Regulator MilestoneEx-US Regulatory
Nasdaq notified Scinai of failure to maintain $1.00 minimum bid price
●Other Regulator MilestonePC111Ex-US Regulatory
Revised €12 million FENG SMART Path grant application submitted for PC111
pemphigus vulgaris, Stevens-Johnson Syndrome/Toxic Epidermal Necrolysissource ↗
▲Partnership / LicensePC111Corporate
Option agreement with Pincell extended to August 31, 2026
severe dermatological conditionssource ↗
●IND SubmissionPC111IND
FENG grant application resubmitted for PC111
severe dermatological conditionssource ↗
●IND SubmissionIND
Two additional FENG grant applications submitted for IL-17 NanoAb programs
◆Oral PresentationPresentation
CEO Amir Reichman to co-lead Biopharma Manufacturing Roundtable at HealthIL Week 2026
◆Manufacturing MilestoneCMC / Inspection
Installation and qualification of new filling system expected
◆Partnership / LicenseCorporate
Exclusive licensing option for four new NanoAbs expected to be exercised by Q1 2026
◆Quarterly UpdateCorporate
Annual General Meeting of Shareholders to be held on December 22, 2025
▼Grant / FundingPC111Corporate
€12 million FENG grant application for PC111 not approved on November 24, 2025
▲Manufacturing MilestoneCMC / Inspection
IIA grant awarded for fill-and-finish system expansion
◆First Patient DosedNanoAbTrial
First-in-human clinical trial expected to commence
plaque psoriasissource ↗
▲PublicationPC111Presentation
New peer-reviewed publication in Journal of Dermatological Treatment validating PC111's disease-modifying potential
pemphigus and SJS/TENsource ↗
▲Partnership / LicensePC111Corporate
Scinai secures strategic option agreement to acquire Pincell srl, licensing PC111
Pemphigus Vulgaris, Stevens-Johnson/Toxic Epidermal Necrolysissource ↗
▲Oral PresentationPC111Presentation
Dr. Roberta Lotti receives 'Oscar of Italian Dermatology' for PC111 research
Pemphigus Vulgarissource ↗
◆Oral PresentationPresentation
CEO Amir Reichman to participate in BIO International Convention 2025
▲Other Regulator MilestoneEx-US Regulatory
Italian government grants Golden Power clearance for acquisition of Pincell
▼Restructuring LayoffsCorporate
Implemented cost-reduction program to lower annual employment expenses by ~$815,000
Past FDA Catalysts and PDUFA Decisions
How SCNI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every SCNI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| anti-IL-17 NanoAbs | mild to moderate plaque psoriasis | 2023-12-12 | significantly reduced IL-17 release (p<0.001); improved skin structure following a single dose; more efficient than Betamethasone in reducing inflammation-induced skin; at least as efficient as CosentyxRead More | Scinai Announces Promising Results in a Psoriatic Human Skin ModelRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SCNI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SCNI for Q2 2026. | ||||
SCNI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SCNI ranks across every disease it competes in
Competitive Position is a premium feature
See how SCNI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSCNI News
SCNI▼ -30.1%today
Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement
Scinai Immunotherapeutics has announced a $4.0 million financing through a private placement and warrant inducement agreement with a life sciences institutional investor. The financing will support the expansion of its contract development and manufacturing organization and its immunotherapy pipeline. The transaction is expected to close around October 15, 2026, pending customary conditions.
Read more →SCNI▲ +8.3%on this news· ran to +22% by day 1
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
Scinai Immunotherapeutics Ltd. has confirmed its compliance with Nasdaq's minimum bid price requirement after maintaining a closing bid price of at least $1.00 for 19 consecutive business days. The company received notification from Nasdaq that the compliance matter is now closed. CEO Amir Reichman expressed appreciation for Nasdaq's support and emphasized the company's focus on commercial execution and advancing its NanoAb programs.
Read more →SCNIScinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
Scinai Immunotherapeutics Ltd. has released its corporate highlights and financial results for the first half of 2026. The company is focusing on its growing contract development and manufacturing organization (CDMO) segment. An investor webinar is set for August 26, 2026, to discuss these developments further.
Read more →SCNIScinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
Scinai Immunotherapeutics has appointed Eran Kuratz as Head of Supply Chain and Business Process Administration for its CDMO subsidiary. Kuratz, with over 30 years of experience, will lead key operational functions to support the company's expanded CDMO platform. This appointment follows Scinai's recent acquisition of Recipharm Israel, enhancing its development and manufacturing capabilities.
Read more →SCNI▼ -7.7%on this news
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
Scinai Immunotherapeutics Ltd. reported its financial results for Q1 2026, highlighting a net income of $3.6 million following the acquisition of Recipharm Israel. The company expanded its CDMO platform, enhancing its manufacturing capabilities and strategic collaborations. However, operating losses increased due to higher expenses associated with the expansion, and revenues saw a decline compared to the previous year.
Read more →SCNI▼ -6%on this news
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
Scinai Immunotherapeutics has appointed Eilon Elmalem as the Site Head of its Yavne CDMO facility, effective June 14, 2026. Elmalem, who has been an external consultant for two years, will oversee site operations and engineering activities. The transition process is under the supervision of the current site head, Dr. Sylvia Kachalsky, who is set to retire later in 2026.
Read more →SCNIScinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
Scinai Immunotherapeutics will lead a roundtable at the 7th Dermatology Drug Development Summit Europe, discussing the impact of oral therapies on biologics. The session will address key questions regarding the efficacy and strategic role of oral peptide and small molecule therapies in immunology. CEO Amir Reichman emphasizes the importance of these discussions for the future of immunology treatments.
Read more →SCNISCINAI IMMUNOTHERAPEUTICS LTD. Jerusalem BioPark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on
Scinai Immunotherapeutics Ltd. announced the scheduling of its Annual General Meeting of Shareholders, which will take place on June 16, 2026, in Tel Aviv, Israel. Shareholders who hold American Depositary Shares (ADSs) on May 13, 2026, will be entitled to attend and vote. The meeting will provide an opportunity for ADS holders to review financial statements for the fiscal year ended December 31, 2025. The proxy materials recommend a "FOR" vote on various proposals, although no additional matters are currently anticipated for discussion.
Read more →SCNIRecipharm Israel Ltd. Audited Financial Statements as of
Recipharm Israel Ltd. has released its audited financial statements for the year ending December 31, 2025, reporting significant losses and a negative equity position. The company experienced a comprehensive loss of NIS 9,395 thousand and reported a working capital deficit of NIS 22,819 thousand. Concerns regarding the company's ability to continue as a going concern have been raised due to its reliance on support from its parent company, Recipharm OT AB. The financial statements reflect a challenging fiscal situation for the company.
Read more →SCNI▲ +61.6%on this news
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
Scinai Immunotherapeutics Ltd. has announced a $2.61 million private placement financing led by an institutional investor. The funds will be used to expand its contract development and manufacturing organization (CDMO) platform and advance customer programs. The closing of the transaction is expected around April 27, 2026, subject to customary conditions.
Read more →SCNIScinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
Scinai Immunotherapeutics has completed a strategic reorganization to create a dedicated CDMO platform, Scinai Biopharma Services, and streamline its R&D operations. This transformation aims to enhance capital efficiency and operational focus, allowing both divisions to operate independently. The company targets approximately $5 million in CDMO revenues for 2026 while advancing key R&D programs.
Read more →SCNI▲ +12.1%on this newsshared move
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
Scinai Immunotherapeutics reported a doubling of CDMO revenues to $1.3 million for the year ended December 31, 2025. The company expanded its capabilities through the acquisition of Recipharm Israel and a strategic collaboration, enhancing its manufacturing services. Despite a net loss of $8.3 million, Scinai is focusing on capital-efficient funding and positioning its lead program, PC111, for growth.
Read more →SCNIScinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
Scinai Immunotherapeutics Ltd. will participate in BIO-Europe Spring 2026, highlighting its enhanced contract development and manufacturing organization (CDMO) following the acquisition of Recipharm Israel. The company aims to engage with pharmaceutical and biotechnology firms to advance its R&D pipeline of innovative antibody-based immunotherapies. Scinai is positioning itself as a flexible partner in the development to commercialization continuum. However, the outlook includes risks related to the recent acquisition and operational integration challenges.
Read more →SCNIScinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
Scinai Immunotherapeutics Ltd. received notice from NASDAQ regarding non-compliance with minimum bid price requirements, as their American Depositary Shares (ADSs) traded below $1.00 for 30 business days. The company has 180 days to regain compliance, providing they maintain the bid price above $1.00 for ten consecutive days. Despite the notification, there is no immediate effect on the trading of their ADSs. Scinai is evaluating its options to meet the listing requirements.
Read more →SCNIScinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
Scinai Immunotherapeutics has signed a Second Amendment to its option agreement for acquiring PinCell S.r.l. and submitted a revised application for €12 million in non-dilutive funding to support its PC111 program. The funding aims to advance PC111, a monoclonal antibody for autoimmune diseases, through early clinical development. The revised application reflects enhancements to project design, with expectations for a funding decision in three to four months.
Read more →SCNI▲ +5.9%on this newsshared move
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
Scinai Immunotherapeutics has received expanded support from the Israel Innovation Authority for its robotic aseptic fill and finish platform, with a total grant of NIS 5 million. This funding will aid in acquiring and validating a fully automated system to meet EU GMP standards. The initiative is part of Scinai's strategy to enhance its CDMO capabilities following its acquisition of Recipharm Israel Ltd. and aims to improve sterile manufacturing processes.
Read more →SCNIScinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
Scinai Immunotherapeutics Ltd. has successfully acquired Recipharm Israel Ltd., significantly enhancing its manufacturing capabilities and expanding its CDMO footprint in Israel. This acquisition is complemented by a long-term strategic commercial collaboration with Recipharm, which will streamline transitions for clients from early-stage development to late-stage manufacturing. The collaboration aims to improve service delivery, manage quality, and reduce costs. Scinai's CEO emphasized the importance of this acquisition in creating an integrated product development pathway and ensuring continuity for Recipharm’s employees and clients.
Read more →SCNIScinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
Scinai Immunotherapeutics' CEO, Amir Reichman, will co-lead a roundtable at HealthIL Week 2026 focused on biopharma manufacturing in Israel. The discussion aims to address the capabilities and gaps in the country's biopharma ecosystem, emphasizing early-stage development and regulatory readiness. Key stakeholders, including government representatives and biopharma manufacturers, are expected to participate.
Read more →SCNIScinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
Scinai Immunotherapeutics reported its financial results for the nine months ending September 30, 2025, highlighting growth in its CDMO business and advancements in its NanoAbs pipeline. The company is actively pursuing partnerships and has submitted grant applications to support its research programs. However, it faced a setback with the non-approval of a significant grant for its PC111 program, prompting a review of its strategic options.
Read more →About Scinai Immunotherapeutics Ltd.
HeadquartersJERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM, L3, 00000
BIOPHARMAWATCH ELITE PLUS
Trade the next SCNI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime